Spanish dermatology specialist Almirall (ALM: MC) has announced that Mike McClellan will join the company as new chief financial officer (CFO) on November 11, 2019.
He will succeed David Nieto, who has decided to step down from his role as CFO. Mr Nieto will ensure a smooth transition with Mike over the next period.
Mr McClellan is currently group CFO and executive vice president at Teva Pharmaceutical Industries (NYSE: TEVA) based in Tel Aviv, Israel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze